AbbVie (ABBV) Stock Falls After Company Denies Revolution Medicines Buyout Talks

TLDR AbbVie stock fell 1% after hours following company’s denial of Revolution Medicines acquisition talks Revolution Medicines shares dropped 11.5% in extended trading after surging 30% during regular session AbbVie cuts 2025 earnings forecast to $9.90-$9.94 per share from previous $10.61-$10.65 guidance Wall Street Journal reported AbbVie was pursuing $20 billion deal for cancer drug [...]

The post AbbVie (ABBV) Stock Falls After Company Denies Revolution Medicines Buyout Talks appeared first on Blockonomi.